MedTrace Logo

Survey on the Clinical Use of Recombinant Human Erythropoietin in VLBW and ELBW Infants

NCT05372211 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-05-12

No results posted yet for this study

Summary

Recombinant human erythropoietin (rhEPO) has been shown to effectively and safely prevent the anemia of prematurity and to reduce the transfusion need in very low birth weight (VLBW) and extremly low birth weight (ELBW) infants and has been licensed for this indication in Europe in 1997. The objective of the study was to obtain information on the use or nonuse of rhEPO in neonatal units in China.

Conditions

  • Erythropoietin; Infant; Surveys and Questionnaires

Interventions

OTHER

not use of any intervention

not use of any intervention

Sponsors & Collaborators

  • Shenzhen People's Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2022-09-01
Completion
2022-10-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05372211 on ClinicalTrials.gov